Interferon regulatory factor 8 expression and features in blastic plasmacytoid dendritic cell neoplasm and extranodal NK/T-cell lymphoma, nasal type

Simple item page
dc.contributor.authorXiaoqin Dai
dc.contributor.authorLi Sun
dc.contributor.authorGe Tang
dc.contributor.authorYu Dong
dc.contributor.authorFenfen Zhang
dc.contributor.authorAnjia Han
dc.contributor.authorYuejiao Lang
dc.contributor.departmentBiología Celular e Histología
dc.date.accessioned2025-11-11T09:10:10Z
dc.date.available2025-11-11T09:10:10Z
dc.date.issued2025
dc.description.abstractAims. To investigate the diagnostic value of Interferon regulatory factor 8 (IRF8) in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and extranodal NK/T-cell lymphoma, nasal type (ENKTL). Methods. Immunohistochemistry staining was used to detect IRF8 expression in 19 cases of BPDCN and 59 cases of ENKTL. In addition, 21 cases of myeloid sarcoma, 30 of B-lymphoblastic leukemia/lymphoma (B-ALL/LBL), 30 of T-lymphoblastic leukemia/lymphoma (T-ALL/LBL), 10 of histiocytic sarcoma, 10 of Langerhans cell histiocytosis, and 9 of follicular dendritic cell sarcoma were also included. DNA sequencing detected IRF8 genetic variation in 6 cases of BPDCN and 20 cases of ENKTL. Results. IRF8 expression was detected in 100.00% (19/19) of BPDCN, exhibiting a strong and uniform staining pattern, and in 91.53% (54/59) of ENKTL, with varying degrees of staining intensity. Weak and focal staining was detected in 33.33% (7/21) of myeloid sarcoma, 13.33% (4/30) of B-ALL/LBL, and 11.11% (1/9) of follicular dendritic cell sarcoma. No expression was found in T-ALL/LBL, histiocytic sarcoma, or Langerhans cell histiocytosis. The proportion of IRF8 positive expression was higher in BPDCN and ENKTL than in other hematolymphoid neoplasms. In ENKTL, the average IRF8 expression was higher in nasal cases than in extranasal cases and in cases with mitosis figures of more than 4/10 high-power field (HPF). Predominant-ly large transformed cell morphology and extranasal involvement site might serve as independent prognostic factors of two-year survival in ENKTL. IRF8 genetic point mutations were found in 33.33% (2/6) of BPDCN and 10.00% (2/20) of ENKTL. Conclusion. The study demonstrated the promising value of IRF8 in the diagnosis of BPDCN and ENKTL.
dc.formatapplication/pdf
dc.format.extent12
dc.identifier.doihttps://doi.org/10.14670/HH-18-913
dc.identifier.eissn1699-5848
dc.identifier.issn0213-3911
dc.identifier.urihttp://hdl.handle.net/10201/172169
dc.languageeng
dc.relationSin financiacion externa a la Universidad
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBlastic plasmacytoid dendritic cell neoplasm
dc.subjectExtranodal NK/T-cell lymphoma
dc.subjectNasal type
dc.subjectImmunohistochemistry staining
dc.subjectDNA sequencing
dc.subjectInterferon regulatory factor 8
dc.subject.odsNo relacionado con ningún objetivo de desarrollo sostenible
dc.titleInterferon regulatory factor 8 expression and features in blastic plasmacytoid dendritic cell neoplasm and extranodal NK/T-cell lymphoma, nasal type
dc.typeinfo:eu-repo/semantics/article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Lang-40-2035-2046-2025.pdf
Size:
2.25 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.37 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology, Vol.40, Nº12, (2025)